Eprodisate Sodium Reduces Risk of Renal Deterioration in Patients With Amyloid A
Posted by: joann on Jul 13, 2006 - 09:55 PM
protein_news
|
[excerpt] The new anti-amyloid agent eprodisate sodium (NC-503) is safe and exerts a clinically meaningful and statistically significant effect on amyloid A (AA) amyloidosis that can result in loss of tissue and organ function in patients with underlying inflammatory conditions, according to a combined international, multicenter, randomized, double-blind, placebo-controlled, phase 2/3 trial.
This study was presented here on June 23rd at the Annual European Congress of Rheumatology (EULAR) on behalf of the Fibrillex Amyloid Secondary Trial (FAST) Group by Bouke P.C. Hazenberg, MD, coinvestigator and consultant in rheumatology, rheumatology, and clinical immunology at the University Medical Centre Groningen in Groningen, The Netherlands.
Amyloidosis is a protein-folding disorder that can occur in diseases characterized by extracellular deposition of insoluble fibrillar proteinaceous material, thereby resulting in loss of function of the tissue or organ involved.
AA amyloidosis occurs in 1% to 5% of patients with sustained high levels of serum AA, and it is characteristic of idiopathic inflammatory diseases (eg, rheumatoid arthritis, JIA, Crohn's disease), chronic infections (eg, tuberculosis, leprosy, bronchiectasis), and hereditary fevers (eg, familial Mediterranean fever).
While current treatment strategies target the initial causes of inflammation that can lead to increased levels of serum AA precursor protein, the new anti-amyloid agent eprodisate more directly prevents polymerization of AA into the aggregates that show resistance to proteolysis.
Read the full story.
|
|
| |
|
